Neurocrine Biosciences | NBIX - Gross Profit On Sales


Neurocrine Biosciences reported $800.7M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cytokinetics USD 19.2M 1.44M Mar/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Prothena USD 21K 2.39M Dec/2025
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Repligen USD 108.28M 4.45M Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xoma 992K 846K Jun/2024